

HR 4475

Compassionate Freedom of Choice Act of 2014

Congress: 113 (2013–2015, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 10, 2014

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Apr 11, 2014)

Official Text: <https://www.congress.gov/bill/113th-congress/house-bill/4475>

Sponsor

Name: Rep. Griffith, H. Morgan [R-VA-9]

Party: Republican • **State:** VA • **Chamber:** House

Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Hanna, Richard L. [R-NY-22]	R · NY		Apr 10, 2014
Rep. Calvert, Ken [R-CA-42]	R · CA		May 9, 2014
Rep. Duncan, John J., Jr. [R-TN-2]	R · TN		Jun 24, 2014
Rep. Salmon, Matt [R-AZ-5]	R · AZ		Nov 12, 2014

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Apr 11, 2014

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
113 HR 5854	Related bill	Dec 11, 2014: Referred to the House Committee on Energy and Commerce.

Compassionate Freedom of Choice Act of 2014 - Amends the Federal Food, Drug, and Cosmetic Act to declare that nothing in it or in the Public Health Service Act shall prevent or restrict, and the Food and Drug Administration (FDA) shall not implement or enforce any law to prevent or restrict, the manufacture, importation, distribution, or sale of investigational drugs or devices for terminally ill patients.

Prohibits the FDA Commissioner from requiring the disclosure, collection, or reporting of certain information concerning such drugs or devices, except that the sponsor of a clinical trial may voluntarily disclose, collect, or report such information to the FDA.

Declares that, except in cases of gross negligence or willful misconduct, any person who manufactures, imports, distributes, prescribes, or administers an investigational drug or device shall not be liable in any action under state or federal law for loss, damage, or injury arising out of, relating to, or resulting from: (1) the design, development, clinical testing and investigation, manufacturing, labeling, distribution, sale, purchase, donation, dispensing, prescription, administration, or use of such drugs or devices; or (2) their safety or effectiveness.

Actions Timeline

- **Apr 11, 2014:** Referred to the Subcommittee on Health.
- **Apr 10, 2014:** Introduced in House
- **Apr 10, 2014:** Referred to the House Committee on Energy and Commerce.